The Roles of Matrix Metalloproteinases in Pancreatic Cancer

被引：57
作者：
Knapinska, Anna M. [1 ]
Estrada, Christie-Anne [1 ]
Fields, Gregg B. [1 ,2 ]
机构：
[1] Florida Atlantic Univ, Jupiter, FL 33458 USA
[2] Scripps Res Inst Scripps Florida, Jupiter, FL 33458 USA
来源：
MATRIX METALLOPROTEINASES AND TISSUE REMODELING IN HEALTH AND DISEASE: TARGET TISSUES AND THERAPY | 2017年 / 148卷
关键词：
TUMOR-GROWTH; IN-VITRO; MATRIX-METALLOPROTEINASE-9; MMP-9; HEMOPEXIN DOMAIN; CELL INVASION; MOUSE MODELS; LINE THERAPY; MT1-MMP; INHIBITION; ANTIBODY;
D O I：
10.1016/bs.pmbts.2017.03.004
中图分类号：
Q5 [生物化学]; Q7 [分子生物学];
学科分类号：
071010 ; 081704 ;
摘要：
Matrix metalloproteinases (MMPs) have long been implicated for roles in cancer initiation, tumor growth, and metastasis. However, pancreatic cancer clinical trials using broad-based MMP inhibitors were discouraging. To better evaluate the use of MMP inhibitors in pancreatic cancer, (a) more precise roles of individual MMPs in pancreatic cancer needed to be determined and (b) animal models that more accurately represented human pancreatic cancer needed to be developed. The last decade has seen substantial progress in both areas. MT1-MMP has been recognized as a critical mediator of several steps in pancreatic cancer progression, while MMP-9 appears to be an antitarget when considering pancreatic cancer therapies.
引用
收藏
页码：339 / 354
页数：16
相关论文
共 55 条
  • [1] Ager EI, 2015, JNCI-J NATL CANCER I, V4, P107
  • [2] Potential clinical implications of recent matrix metalloproteinase inhibitor design strategies
    Amar, Sabrina
    Fields, Gregg B.
    [J]. EXPERT REVIEW OF PROTEOMICS, 2015, 12 (05) : 445 - 447
  • [3] Inhibition of MT1-MMP activity using functional antibody fragments selected against its hemopexin domain
    Basu, B.
    de Sampaio, P. Correa
    Mohammed, H.
    Fogarasi, M.
    Corrie, P.
    Watkins, N. A.
    Smethurst, P. A.
    English, W. R.
    Ouwehand, W. H.
    Murphy, G.
    [J]. INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY, 2012, 44 (02) : 393 - 403
  • [4] Orally Active MMP-1 Sparing α-Tetrahydropyranyl and α-Piperidinyl Sulfone Matrix Metalloproteinase (MMP) Inhibitors with Efficacy in Cancer, Arthritis, and Cardiovascular Disease
    Becker, Daniel P.
    Barta, Thomas E.
    Bedell, Louis J.
    Boehm, Terri L.
    Bond, Brian R.
    Carroll, Jeffery
    Carron, Chris P.
    DeCrescenzo, Gary A.
    Easton, Alan M.
    Freskos, John N.
    Funckes-Shippy, Chris L.
    Heron, Marcia
    Hockerman, Susan
    Howard, Carol Pearcy
    Kiefer, James R.
    Li, Madeleine H.
    Mathis, Karl J.
    McDonald, Joseph J.
    Mehta, Pramod P.
    Munie, Grace E.
    Sunyer, Teresa
    Swearingen, Craig A.
    Villamil, Clara I.
    Welsch, Dean
    Williams, Jennifer M.
    Yu, Ying
    Yao, Jun
    [J]. JOURNAL OF MEDICINAL CHEMISTRY, 2010, 53 (18) : 6653 - 6680
  • [5] Bhowmick M, 2017, J MED CHEM IN PRESS
  • [6] Matrix Metalloproteinase Inhibition by Heterotrimeric Triple-Helical Peptide Transition State Analogues
    Bhowmick, Manishabrata
    Stawikowska, Roma
    Tokmina-Roszyk, Dorota
    Fields, Gregg B.
    [J]. CHEMBIOCHEM, 2015, 16 (07) : 1084 - 1092
  • [7] Matrix metalloproteinases and their role in pancreatic cancer: A review of preclinical studies and clinical trials
    Bloomston, M
    Zervos, EE
    Rosemurgy, AS
    [J]. ANNALS OF SURGICAL ONCOLOGY, 2002, 9 (07) : 668 - 674
  • [8] Development of a specific affinity-matured exosite inhibitor to MT1-MMP that efficiently inhibits tumor cell invasion in vitro and metastasis in vivo
    Botkjaer, Kenneth A.
    Kwok, Hang Fai
    Terp, Mikkel G.
    Karatt-Vellatt, Aneesh
    Santamaria, Salvatore
    McCafferty, John
    Andreasen, Peter A.
    Itoh, Yoshifumi
    Ditzel, Henrik J.
    Murphy, Gillian
    [J]. ONCOTARGET, 2016, 7 (13) : 16773 - 16792
  • [9] A double-blind placebo-controlled, randomised study comparing gemcitabine and marimastat with gemcitabine and placebo as first line therapy in patients with advanced pancreatic cancer
    Bramhall, SR
    Schulz, J
    Nemunaitis, J
    Brown, PD
    Baillet, M
    Buckels, JAC
    [J]. BRITISH JOURNAL OF CANCER, 2002, 87 (02) : 161 - 167
  • [10] Marimastat as first-line therapy for patients with unresectable pancreatic cancer: A randomized trial
    Bramhall, SR
    Rosemurgy, A
    Brown, PD
    Bowry, C
    Buckels, JAC
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (15) : 3447 - 3455
123456